Tag: Elixir Medical
TCT 2024: Six-month data reflect safety and efficacy of Lithix HC-IVL system
Six-month data from the PINNACLE I study evaluating the safety and performance of the LithiX Her...
TCT 2024: Coronary bioadaptor shows clinical benefit in complex PCI sub-groups
Late-breaking data from the INFINITY SWEDEHEART trial demonstrate significant benefit of the Dyn...
ESC 2024: Coronary bioadaptor non-inferior to DES at one-year for TLF
The DynamX (Elixir Medical) bioadaptor system met non-inferiority at one year for target lesion fail...
DynamX sirolimus-eluting bioadaptor system gains US FDA breakthrough designation
Elixir Medical has announced that its novel bioadaptive implant, the DynamX sirolimus-eluting co...
INFINITY-SWEDEHEART trial of DynamX bioadaptor system completes enrolment
Elixir Medical has announced enrolment completion in INFINITY-SWEDEHEART, a prospective, multice...
Enrolment completed in BIOADAPTOR trial of Dynamx coronary implant
Elixir Medical has announced completion of enrolment in the BIOADAPTOR randomised controlled tri...
TCT 2017: Elixir reveals new drug-eluting stent
Elixir Medical unveiled for the first time its novel stent technology—Dynamx—at the 2017 Transca...
TCT 2017: Elixir Medical to reveal “a game-changing metallic drug-eluting stent platform”
Elixir Medical has revealed details of its programme and activities during the 2017 meeting of the t...
TCT 2016: “Excellent” rates of late lumen loss with Desolve bioresorbable scaffold
Six-month clinical data for Elixir Medical’s bioresorbable scaffold (Desolve) were presented at the ...
TCT 2016: First live case featuring Desolve NXT scaffold to be presented
Elixir Medical has announced that it will showcase the first live case demonstration by transmission...
